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Adequate perception of immunologically important pathogen-associated molecular
patterns like lipopolysaccharide and bacterial lipoproteins is essential for efficient
innate and adaptive immune responses. In the context of Gram-negative infection,
bactericidal/permeability-increasing protein (BPI) neutralizes endotoxic activity of
lipopolysaccharides, and thus prohibits hyperactivation. So far, no immunological
function of BPI has been described in Gram-positive infections. Here, we show a
significant elevation of BPI in Gram-positive meningitis and, surprisingly, a positive
correlation between BPI and pro-inflammatory markers like TNFα. To clarify the
underlying mechanisms, we identify BPI ligands of Gram-positive origin, specifically
bacterial lipopeptides and lipoteichoic acids, and determine essential structural motifs
for this interaction. Importantly, the interaction of BPI with these newly defined ligands
significantly enhances the immune response in peripheral blood mononuclear cells
(PBMCs) mediated by Gram-positive bacteria, and thereby ensures their sensitive
perception. In conclusion, we define BPI as an immune enhancing pattern recognition
molecule in Gram-positive infections.
Keywords: bactericidal/permeability-increasing protein, pro-inflammatory, bacterial lipoprotein, lipoteichoic acid,
Streptococcus pneumoniae, Gram-positive, pattern recognition
INTRODUCTION
Pathogen-associated molecular patterns (PAMPs) of bacterial origin like lipopolysaccharide (LPS)
are recognized by innate immune cells via a variety of pattern recognition receptors. In more
detail, LPS is sensed by Toll-like receptor 4 (TLR4) in cooperation with CD14 and MD2 as
well as BAI1 and Caspase-4/5 (1). In Gram-positive infections, the most important PAMPs
are bacterial lipopeptides and lipoproteins [bLPs; (2, 3)]. Their extracellular recognition is
mediated by TLR2 (2, 3). In this process, formation of a heterodimer between TLR2 and
TLR6 or TLR1 is essential for the perception of di-acylated or tri-acylated bLPs, respectively
(4, 5). Additionally, the co-receptors CD14 and, in case of di-acylated bLPs, CD36 are
involved and associate with the TLR2/TLR6 or TLR2/TLR1 dimer (6–8). As a soluble factor,
lipopolysaccharide binding protein (LBP) also contributes to the recognition of both LPS and bLPs
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by transferring these PAMPs to the CD14/TLR complexes (6,
9–11). Lipoteichoic acid (LTA) is another major component
of the cell wall of Gram-positive bacteria. Lipoteichoic acids
(LTAs) extracted from wild-type strains were described as TLR2
ligands (10, 12, 13). Indeed, LTA binds to TLR2, but is not
sufficient to initiate TLR2 heterodimerization with TLR1 or
TLR6 and consecutive signaling (5). Accordingly, LTA free of
bLPs does not trigger TLR2 and is overall low- or even non-
immunostimulatory (2, 14, 15). The responsible structural motifs
for residual immunostimulation are not completely clarified
yet, but in LTA of Streptococcus pneumoniae (SP) these are
most likely the P-Cho residues present in teichoic acids, which
activate the lectin complement pathway via human L-ficolin
(16).
Bactericidal/permeability-increasing protein (BPI) is a
neutrophil-derived protein described as the prototype of the
tubular-lipid binding protein (TULIP) family (17, 18). Although
showing a 44% sequence identity to LBP at the amino acid
level (19), BPI has been described as the natural antagonist
of LBP since the interaction of BPI with its ligand LPS is
strong enough to prohibit the LPS-dependent stimulation
of immune cells (20–22). This function depends on the
highly cationic amino-terminal half of BPI, which fully
expresses the LPS-binding potential as well as its bactericidal
properties toward Gram-negative bacteria seen in holo-BPI
(23). Although structurally similar to the N-terminal part
(24), the C-terminal part of BPI displays no bactericidal or
LPS-binding activities (25). Nevertheless, it contributes to the
opsonization of Gram-negative bacteria, and is responsible
for the binding of BPI to peripheral blood mononuclear cells
(PBMCs) via a yet unknown receptor (26–28). The functional
difference between BPI and LBP depends on the carboxy-
terminal half of both proteins (29) and is mainly caused by
structural characteristics in this region of the protein, thereby
distinguishing LBP from BPI (19). However, N-terminal parts
of both proteins show high levels of structural and functional
similarity (19, 29). In addition to LPS, the N-terminal half of
LBP also binds LTA and bLPs (9, 10). These lipid-containing
bacterial cell wall components of Gram-positive origin have
not been evaluated for BPI yet, presumably because BPI is
described as non-bactericidal toward Gram-positive bacteria
(30, 31). Although BPI is released in both Gram-negative
and -positive bacteremia and sepsis (32, 33), its physiological
role in Gram-positive infection has not been addressed so
far.
In the present study, we describe a significant elevation
of BPI in the cerebrospinal fluid (CSF) of patients with
Gram-positive bacterial meningitis. Moreover, we show specific
binding of BPI to bLPs and LTA as well as BPI-mediated
enhancement of the immune response toward these ligands.
In conclusion, we determine that BPI is a highly conserved
pattern recognition molecule contributing to the perception
of bLPs, LTA, and Gram-positive bacteria in general. This
novel finding contributes to the fundamental understanding
of the function of this highly expressed defense protein and
the mechanisms by which the immune system detects bacterial
infections.
MATERIALS AND METHODS
Reagents
Bactericidal/permeability-increasing protein (BPI) extracted
from neutrophils was purchased from Athens Research and
Technology [Athens, GA, USA; BPIN(A)] and Wieslab AB
[Malmö, Sweden; BPIN(W)]. Tri-acylated [Pam3CSK4, (R)-
Pam3CSK4, (S)-Pam3CSK4, Pam3CSK4 Fluorescein], di-acylated
[(R)-Pam2CSK4, (R)-Pam2∗CSK4, Pam2CSK4 biotin, (R)-FSL-1]
and mono-acylated lipopeptides (PamCSK4) came from EMC
Microcollections (Tübingen, Germany). Ultrapure LPS and
LPS biotin both from Escherichia coli (EC) O111:B4 (LPS EC;
LPS EC biotin) as well as peptidoglycan (PGN) purified from
Staphylococcus aureus (SA), heat-killed lysates of E. coliO111:B4,
Staphylococcus aureus and Streptococcus pneumoniae (SP) were
purchased from Invivogen (San Diego, CA, USA). CFU/ml of the
lysates are indicated according to the manufacturers declaration.
Diacyl-glycerol 16:0 (DAG; Avanti Polar Lipids, Alabaster, AL,
USA) dissolved in chloroform was lyophilized, solubilized in
PBS, and sonicated before use. Due to the heterogeneity of the
LPS of E. coli O111:B4 (34) an average molecular weight (MW)
of 15 kDa was estimated by using gel electrophoresis. This is
consistent with data provided by another distributor of LPS
EC (35). PBS (Dulbecco’s Phosphate Buffered Saline, endotoxin
tested; Sigma Aldrich, Taufkirchen, Germany) was used for
storage of recombinant BPI (rBPI), generation of bacterial
lysates, BPI binding assay and NanoDSF.
Cloning, Production, and Purification of
Recombinant BPI
The expression construct was obtained by combining the
sequences of an N-terminal HA signal peptide, the human
BPI (aa 32-487) and a C-terminal FLAG Tag by standard
cloning techniques into pCR3 Vector (Invitrogen, Carlsbad,
CA, USA). In brief, HEK293T cells were transfected using the
calcium phosphate mediated method. The expressed protein
was purified by affinity chromatography on an anti-Flag M2
(Sigma Aldrich, Taufkirchen, Germany) coupled NHS-activated
HP column (GE Healthcare, Chalfont St. Giles, Great Britain)
and elution was performed with PBS containing 150µg/ml
FLAG-Peptide (Sigma Aldrich, Taufkirchen, Germany). The
fractions containing the recombinant protein were concentrated
via a stirred ultrafiltration cell (Amicon R© Ultracel PL-10, Merck
Millipore, Darmstadt, Germany) and dialyzed against PBS.
Bacterial Strains and Preparation of
Bacterial Lysates
Streptococcus pneumoniae strains D391cps, D391cps1lgt,
D391cps1lsp, and D391cps1lgt1lsp [all non-encapsulated
mutants of serotype 2 wild-type D39 (36, 37)], as well as S.
aureus strains 113 and 1131lgt [(3); kindly provided by F. Götz,
University of Tübingen, Germany] were cultured on Columbia
blood agar plates. Bacterial concentrations were determined
by measuring the absorbance at 600 nm. The cell suspension
was washed (3,750 × g) and resuspended to the desired
concentration. To prepare the bacterial lysates, the suspension
was heated at 65◦C for 30min under gentle agitation. Lysates
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were tested for viability as shown in Figure S1. The protein
concentrations of the bacterial lysates were determined using
the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific,
Waltham, MA, USA) to omit differences caused by bacterial
clotting or autolysis.
Isolation of Bacterial Cell Wall Components
Extraction and purification of LTA from S. pneumoniaeD391cps
(LTA SP) and D391cps1lgt (LTA SP1lgt) as well as S. aureus 113
(LTA SA) and 1131lgt (LTA SA1lgt) were performed according
to our published protocols (14). Hydrazine (N2H4) treatment of
S. pneumoniae LTAs and preparation of the PGN-wall teichoic
acid complex (WTA) after LytA treatment from S. pneumoniae
D391cps1lgt were performed as described (38). Average MWs
chosen for calculation of LTA concentrations are based on major
signals (LTA molecules with 6 repeats) in mass spectrometry
[LTA SP1lgt: 8,500 Da; LTA SP1lgt-N2H4: 8,050 Da; (14)], or
average chain length as determined by 1H NMR (LTA SA: 4,500
Da) using a published methodology (39). In contrast to the
structure of the repeating units, the exact chemical composition
of the pneumococcal PGN-WTA macromolecule is not known,
especially with regard to the ratio of [MurNAc-GlcNAc]-units
and WTA chains. Therefore, the MW of the latter cannot be
determined exactly. The MW for a pneumococcal WTA chain
with 6 repeats without PGN-fragments is around 7,900 Da
(40). In order to ensure that the molecular concentration of
the PGN-WTA complex of S. pneumoniae D391cps1lgt (WTA
SP1lgt) exceeded that of LTA SP1lgt in our assays, the applied
molecular concentration of WTA SP1lgt was increased 2-fold to
the calculated one.
Escherichia coli (EC) BL21 (DE3, Novagen) was grown
aerobically with shaking (150 rpm) at 37◦C in standard LB
medium (Invitrogen, Carlsbad, CA, USA) containing 5 g/l of
NaCl until an absorbance of approximately 0.8 at 600 nm was
reached. LPS was extracted by a combination of hot phenol-
water (41) and PCP I extraction (42). Phenol (90%) was added
to reach a final concentration of 1% and the resulting suspension
was shaken (150 rpm) for 1 h at 37◦C. Cells were collected by
centrifugation (9,000× g, 20min, 4◦C) and subsequently washed
three times with water (centrifugation conditions as above). The
lyophilized pellet was washed with ethanol, acetone (twice), and
diethyl ether, and then dried. Cells were resuspended in water
(∼20 mg/ml), sequentially treated for 16 h at room temperature
with DNase and RNase and 8 h with proteinase K (each at
∼20µg/ml), dialyzed for 1 day at 4◦C against water (three
water exchanges) and lyophilized. LPS was further extracted
by phenol-chloroform-petroleum ether extraction. The pellet
was suspended in phenol (90%)-chloroform-petroleum ether
[40–60◦C, 2:5:8 (vol/vol/vol); 95 mg/ml] with an Ultra-Turrax,
then the mixture was stirred for 30min at room temperature
and the supernatant was collected after centrifugation (7,650
× g, 20min, 4◦C). The extraction process was repeated twice
and the supernatants were then combined and evaporated in
a vacuum (50–55◦C) until phenol crystallization began. LPS
was precipitated in the cold by the addition of water (phenol
concentration >80%), then samples were centrifuged (4,300
× g, 20min, 20◦C) and washed twice with 80% phenol and
three times with acetone (centrifugation conditions as above).
A final lyophilization step yielded the LPS. A small portion
of this LPS was further purified by reversed phase HPLC as
previously described (43) using a modified gradient: The initial
solvent system (2% B) was maintained for 20min, followed
by a linear two-step gradient rising from 2 to 17% B (20–
50min) and 17 to 20% B (50–60min). The solvent was kept
for 20min at 20% B, followed by a linear gradient rising from
20 to 27% B (80–105min). To ensure removal of all residual
components, the solvent was kept for 30min at 27% B, followed
by a linear gradient rising from 27 to 40% B (135–140min),
kept at 40% B for 10min, raised in 10min by a linear gradient
to 100% B and maintained for 5min. Finally, the column was
re-equilibrated for 10min to 2% B and was maintained at that
level for at least 10min before the next injection. The pool
used for the experiments contained LPS with a monoisotopic
molecular mass of 3,770.723 Da as its main component,
which is in line with published data for E. coli BL21 (DE3)
LPS [LPS EC BL21; LAhexa+Kdo2+Hep3+Hex+HexA+P+P-
Etn2+Ara4N; (44)], and a second LPS with a mass of 3,762.692
Da (Ara4N exchanged by P-Etn). For the injection (sample
concentration, 4 mg/ml), methanol-chloroform-water [57:12:31
(vol/vol/vol)] containing 10mM NH4OAc and 0.1M Na-EDTA,
pH 7 [4:1 (vol/vol)] was used.
BPI Microtiter Binding Assay
BPI binding assays were performed using a protocol published
for LBP (9) with somemodifications. Streptavidin-coated 96-well
plates (NuncTM ImmobilizerTM Streptavidin F96 clear, Thermo
Fisher Scientific, Waltham, MA, USA) were coated with LPS
biotin (2µg/ml) or Pam2CSK4 biotin (1µg/ml) in PBS overnight
at 23◦C with gentle agitation. After washing with assay buffer
(150mM NaCl, 50mM HEPES, Sigma Aldrich, Taufkirchen,
Germany) containing 0.01% Casein, plates were blocked with
10 g/l BSA (Sigma Aldrich, Taufkirchen, Germany) at 37◦C
and washed again. Thereafter, ligands were preincubated with
20 nM BPI in assay buffer containing 1 g/l BSA for 30min
and loaded onto the plates. In case of bacterial lysates, 0.05%
Tween 20 was added for preincubation. After incubation for
1 h at 37◦C, three washing steps were performed. Bound BPI
was detected by murine anti-human BPI monoclonal antibody
(Cat.-No. HM2042, Hycult Biotech, Uden, Netherlands) and
HRP-conjugated rabbit anti-mouse IgG (Cat.-No. 315-035-048,
Dianova, Hamburg, Germany). TMB (BD OptEIATM TMB
Substrate Reagent Set, BD Biosciences, Heidelberg, Germany)
was used as a substrate for peroxidase. After addition of 1N HCl,
absorbance was measured at 450 nm. Technical replicates were
performed at least two times using exactly the same reagents
and are not indicated for the BPI microtiter binding assay.
Biological replicates shown here are experiments independently
performed by using separately formulated solutions of the
reagents.
Microscale Thermophoresis Experiments
BPIN(A) and rBPI were labeled with NT647 in PBS pH 7.4
(Monolith NTTM Protein Labeling Kit RED—NHS, NanoTemper
Technologies, Munich, Germany). Concentration of labeled
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protein was determined using the NanoDrop (ThermoScientific,
Wilmington, NC, USA) and Bradford assay (Promega,
Mannheim, Germany). MicroScale Thermophoresis (MST)
binding experiments were carried out with 5 nM labeled protein
in binding buffer (10mM HEPES pH 7.4, 150mM NaCl, 0.1%
Tween) with 0.05–1,679 nM of LPS EC or 0.196–6,436 nM of
Pam3CSK4 or 0.61–20,000 nM of LTA SA1lgt and LTA SP1lgt or
of >0.61–20,000 nM WTA SP1lgt at 20–40% MST power, 20%
LED power in premium capillaries on a Monolith NT.115 pico
device at 25◦C (NanoTemper Technologies, Munich, Germany).
For MST binding assays based on Pam3CSK4 Fluorescein,
20 nM of the fluorescent molecule in binding buffer (10mM
HEPES pH 7.4, 150mM NaCl, 0.1% Tween) was supplied with
0.018–600 nM BPIN(A) and measured at 40% MST power, 10%
LED power in premium capillaries on a Monolith NT.115 pico
device at 25◦C (NanoTemper Technologies, Munich, Germany).
MST timetraces were recorded and the temperature jump
or, respectively, thermophoresis was analyzed. The recorded
fluorescence was plotted against the ligand concentration and
curve fitting was performed with KaleidaGraph 4.5 using the
dissocation constant (KD) fit formula derived from the law
of mass action. For better comparability, binding graphs were
normalized to the fraction bound by the labeled partner (0 =
unbound, 1 = bound). Technical and biological replicates are
defined as described for BPI microtiter binding assays.
NanoDSF Experiments to Determine
Thermal Stability
For thermal unfolding experiments, rBPI protein was diluted to
a final concentration of 5µM in PBS pH 7.4, either containing
a ligand at 30µM concentration [(R)-Pam3CSK4, (R)-FSL-1 or
LPS EC] or in the absence of a ligand. For each condition,
10 µl of sample per capillary were prepared. The samples
were loaded into UV capillaries and experiments were carried
out using the Prometheus NT.48 (NanoTemper Technologies,
Munich, Germany). The temperature gradient was set to an
increase of 1◦C/min with a range from 20 to 90◦C. Protein
unfolding wasmeasured by detecting the temperature-dependent
change in tryptophan fluorescence at emission wavelength of
350 nm (Figure 3E, upper panel). Melting temperature (Tm) was
determined by detecting the maximum of the first derivative of
the fluorescence wavelength 350 nm. For this purpose, an 8th
order polynomial fit was calculated for the transition region
(Figure 3E, lower panel). Next, the first derivative of the fit
was formed and the peak position (at Tm) was determined.
Finally, Tm shift (Tm protein alone — Tm protein with ligand)
upon addition of ligand to the protein (in◦C) was calculated.
Technical and biological replicates were defined as described for
BPI microtiter binding assays.
Measurement of BPI, LPB, and Cytokines
in CSF
All available leftover samples of CSF stored in the Institute
of Clinical Microbiology and Hygiene, University Hospital
Regensburg in the time between 2013 and 2017 and tested
positive in culture and/or PCR for either S. pneumoniae or
Neisseria meningitidis were analyzed. No co-infections were
present as tested by culture and/or PCR. Control samples were 20
leftover samples as indicated above tested positive for enterovirus
as tested by PCR. All samples were pseudonymized. BPI, LBP, and
cytokines in CSF were determined using Luminex R© technology
(Austin, TX, USA). BPI and LBP were measured using specific
antibody pairs (αBPI capture antibody 3F9 and αBPI detection
antibody 4H5, Hycult Biotech, Uden, Netherlands; αLBP capture
antibody biG43 and αLBP detection antibody biG412, Biometec,
Greifswald, Germany). Biotinylation of the detection antibodies
was performed using the Lightning-Link R© Biotin Conjugation
Kit (Innova Biosciences, Cambridge, UK). Cytokines were
determined with the ProcartaPlex R© Multiplex Immunoassay
(eBioscience, Santa Clara, CA, USA).
Isolation and Stimulation of Human
Peripheral Blood Mononuclear Cells
After informed consent, blood was drawn from healthy male
volunteers using heparinized blood collection tubes (Li-Heparin-
Gel-Monovette, Sarstedt, Nümbrecht, Germany) and diluted in
RPMI 1640 (Biochrom, Berlin, Germany) at a ratio of 1:1.5.
The blood was centrifuged in leucosep tubes containing Ficoll R©
Paque plus (Oxford Immunotec, Abingdon, Great Britian) at
1,000 × g for 10min. The interphase containing the leukocytes
was collected and subsequently washed twice with RPMI 1640.
The pellet was resuspended in AIM V R© Medium (Thermo
Fisher Scientific, Waltham, MA, USA), counted and cultivated
in 96-well plates for 4 h (1 × 105/100 µl). Then cells were
stimulated with the indicated compounds in the presence or
absence of BPI. The supernatants were collected after 18 h for
determination of cytokine concentration by ELISA according
to the manufacturer’s instructions (OptEIATM Human TNFα
ELISA Set and OptEIATM Human IL6 ELISA, BD Biosciences,
Heidelberg, Germany; DuoSet R© ELISA human CXCL8/IL-8,
R&D, Minneapolis, MN, USA).
Transfection and Stimulation
HEK293T cells were transfected using the calcium phosphate
mediated method according to a published protocol (45).
Transfections were performed using plasmid vectors for human
TLR2 and human CD14 (both a kind gift of Carsten Kirschning,
University of Duisburg-Essen, Germany) at concentrations of
0.4 and 0.05µg/ml, respectively. A GFP encoding plasmid
(0.4µg/ml) was used as control. For stimulation, transfected
HEK293T cells were cultured at 2 × 105 cells/ml in 96-
well plates and stimulated with (R)-Pam3CSK4 ± BPI. After
24 h, supernatants were collected and analyzed for secretion of
IL-8 by ELISA (DuoSet R© ELISA human CXCL8/IL-8, R&D,
Minneapolis, MN, USA).
Ethics Statement
This study was carried out in accordance with the
recommendations of the Declaration of Helsinki. All donors of
PBMCs gave written informed consent in accordance with the
Declaration of Helsinki. Diagnostic leftover samples stored at
the Institute of Clinical Microbiology and Hygiene, University
Hospital Regensburg, were used for CSF analysis. The protocol
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for both isolation of PBMCs and CSF analysis was approved by
the local ethics committee (Ethikkommision an der Universität
Regensburg).
Statistical Analysis
All analyses were performed using GraphPad Prism, version 7.01
(GraphPad Software, San Diego, CA, USA). Results are depicted
as means ± standard deviation (SD) or means ± standard error
of mean (SEM). Statistical tests were performed as described in
the figure legends.
RESULTS
BPI Is Increased in Gram-Positive
Meningitis
Sepsis and bacteremia can be polymicrobial. In order to evaluate
the increase of BPI in Gram-positive infections, we analyzed
the CSF of patients with bacterial meningitis as in this specific
host compartment co-infections are very unlikely and were
additionally excluded by culture and/or PCR. In the case of
Gram-positive meningitis, we focused on S. pneumoniae (n =
13), and in Gram-negative meningitis on N. meningitidis (n= 7).
CSF of patients infected with enterovirus were used as control (n
= 20). The protein level of BPI was significantly increased in both
S. pneumoniae and N. meningitidis meningitis as compared to
the control group. However, no statistically significant difference
was found between S. pneumoniae andN.meningitidismeningitis
(Figure 1A). Interestingly, in S. pneumoniae meningitis BPI
positively correlated with expression levels of TNFα (r = 0.750,
p = 0.003) and interleukin-6 (IL-6; r = 0.729, p = 0.005;
Figure 1B). Although the pro-inflammatory role of LBP toward
Gram-positive ligands has been well-established (9, 10), no
correlation was found for LBP with either BPI (r = 0.413,
p = 0.161; Figure 1C) or TNFα (r = 0.115, p = 0.709)
and IL-6 levels (r = 0.407 and p = 0.106; Figure 1D) in
S. pneumoniae meningitis. Contrary, in CSF of patients with
meningitis caused by N. meningitidis, no tendency was observed
for a positive correlation between BPI and either TNFα or IL-
6 levels (Figure S2). In sum, BPI is elevated in S. pneumoniae
meningitis and positively correlates with TNFα and IL-6 levels
independently of LBP.
BPI Binds to bLPs in Competition With LPS
The N-terminal parts of BPI and LBP show high structural
and functional similarity (19, 29) and are responsible for their
respective potential to associate with LPS (23, 46). By comparing
these two proteins, we hypothesized that TLR2-activating bLPs
(2, 3) are potential ligands of BPI since they are also bound
by LBP (9, 10). Binding of LBP to LPS can be inhibited with
bLPs, as seen in a solid-phase LBP-binding assay (9, 10). After
optimization of this assay for our purposes, binding of rBPI could
be detected in wells coated with LPS biotin, but not in uncoated
wells (Figure 2A). Furthermore, binding of rBPI was gradually
inhibited by pre-incubation of rBPI with increasing doses of LPS
of E. coli O111:B4 (LPS EC, Figure 2A). To avoid contamination
with bLPs, commercially available ultrapure preparations of LPS
were used for this purpose. Next, synthetic analogs of bLPs
were tested. Interestingly, pre-incubation of rBPI with the tri-
acylated lipopeptide Pam3CSK4 also inhibited binding of rBPI
to LPS in a dose-dependent manner (Figure 2B). Pam3CSK4 is
a racemate of (R)-Pam3CSK4 and (S)-Pam3CSK4, whereas the
natural occurring enantiomer in bLPs is comprised of the (R)-
form only. Therefore, both enantiomers were compared and a
superior binding of (R)-Pam3CSK4 was observed (Figure 2C).
When the di-acylated lipopeptide Pam2CSK4 biotin was used
instead of LPS biotin for coating the plates, gradual inhibition of
rBPI binding was observed for both LPS EC and (R)-Pam3CSK4
(Figures 2D,E). This strongly suggested that masking of LPS
biotin by the bLPs can be excluded as the reason for the inhibitory
effects. Moreover, the cell wall component PGN, as exemplified
by PGNof S. aureus, did not inhibit binding of rBPI to LPS biotin,
confirming the specificity of the test (Figure 2F). Interestingly,
when commercially available heat-inactivated bacteria were
tested, not only the Gram-negative, LPS-containing bacterium E.
coli, but also Gram-positive, endotoxin-tested bacteria S. aureus
and S. pneumoniae inhibited binding of rBPI to LPS biotin-
coated plates (Figure 2G). This observation clearly implies that
Gram-positive bacteria indeed contain ligands of BPI. Since
rBPI was used for most of the experiments, we compared rBPI
to BPI originating from neutrophils (BPIN) by using different
commercial preparations [BPIN(A), BPIN(W)]. All of these were
similarly inhibited with respect to their binding to LPS biotin-
coated wells by pre-incubation with (R)-Pam3CSK4 (Figure 2H).
Hence, we show the presence of BPI binding partners in
Gram-positive bacteria and newly identify bacterial lipopeptides
as ligands. The binding competition between LPS and bLPs
suggests the presence of a common binding site for both ligands
in BPI.
BPI Binds to bLPs With High Affinity
MST was used to compare the interaction between BPI and its
ligands and to determine the affinities when the binding partners
are in solution. An advantage of this method is that visual control
of the binding curves allows optimization of the technical setup
to avoid aggregation and unspecific adsorption to the surface
(47, 48). When BPIN labeled with NT647 was tested by MST for
its affinity to LPS EC, it exhibited strong binding with a KD in a
low nanomolar range (Figure 3A). Binding of the corresponding
rBPI NT647 to LPS EC was comparable to that measured for
BPIN(A) NT647, although a tendency toward lower affinity for
rBPI was detected (KD 17.8± 5.3 nM, Figure 3B). Since the MW
of LPS EC is heterogenic due to natural variability in the length
of the polysaccharide (34), the KD value of rBPI to LPS was
controlled with the defined rough-type LPS EC BL21 (MW 3.77
kDa). This KD tended to be higher but was not decidedly different
(72.6± 15.1 nM) compared to LPS EC (Figure 3B).
Next, the interaction between BPI and bLPs was assessed.
Pam3CSK4 bound to BPIN(A) NT647 with a high affinity
(Figure 3C). Although working under strict low endotoxin
conditions, we wanted to exclude contamination with LPS.
Therefore, Pam3CSK4, covalently labeled with fluorescein, was
tested for binding to unlabeled BPIN(A) (Figure 3D). Indeed,
the KD was similar, or even lower, compared to that observed
for binding of Pam3CSK4 to BPIN(A) NT647, proving that
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FIGURE 1 | Correlation of BPI with pro-inflammatory markers in Gram-positive meningitis. BPI was measured in CSF of patients with bacterial meningitis caused by
Streptococcus pneumoniae (SP, n = 13), Neisseria meningitidis (NM, n = 7) and enterovirus-infected controls (EnV, n = 20). (A) Results are expressed as means ±
SEM. Statistics for comparison of the difference of the BPI level were performed with the unpaired Student’s t-test (p-values are indicated). Correlation of BPI with
TNFα and IL-6 (B) and LBP (C) as well as correlation of LBP with TNFα and IL-6 (D) are depicted. Correlation was analyzed using Pearson’s correlation (r- and
p-values are indicated). Logarithmic values were used for statistical testing.
Pam3CSK4 Fluorescein itself binds to BPI. (R)-Pam3CSK4 also
bound to rBPI NT647 (KD 161.5 ± 23.5 nM, Figure 3B).
Nevertheless, as seen for LPS EC, the affinity was not as strong
as observed for BPIN(A) NT647.
The interaction of a protein with its ligand may result either
in stabilization of the protein, and consecutively in an increase in
melting temperature (Tm), or in destabilization with a decrease
in Tm. To further elucidate this hypothesis, NanoDSF was
performed. When rBPI was incubated with different ligands,
including LPS EC, (R)-Pam3CSK4, (R)-Pam2CSK4, and (R)-FSL-
1, an impressive decrease in Tm was found (Figures 3E,F).
In addition to the solid phase BPI binding assay, we
demonstrated interactions between BPI and synthetic bLPs using
MST and NanoDSF. Affinity of BPI to (R)-Pam3CSK4 was within
a nanomolar range, but lower than that toward LPS EC as
determined by MST.
Binding of BPI to bLPs Depends on Both
the Pattern of Acylation and the Structure
of the Residual Peptide
Although LBP also binds bLPs (9, 10), the exact structural
motifs for this interaction have not been determined yet. As
shown in Figure 4, bLPs consist of a glycerol-core modified by
two fatty acids and cysteine, leading to the diacyl-thioglycerol
motif, which is crucial for TLR2-sensing of bLPs (4, 5). The
cysteine is linked to a residual peptide at its C-terminus in all
bLPs, and additionally to a fatty acid at its N-terminus in tri-
acylated, but not in di-acylated bLPs (49). In order to investigate
which structural motif of the bLPs is crucial for binding to BPI,
variations of bLPs were compared to (R)-Pam3CSK4, which was
the synthetic bLP with the highest affinity to BPI observed so
far (Figure 4A). Deletion of the acyl-chain at the O-2-position
of the thioglycerol core (Pam2∗CSK4) or at the amino-terminal
cysteine of the residual peptide [(R)-Pam2CSK4], each resulted
in a lower inhibitory potential (Figures 4B,C). Exchange of
the residual peptide with a less positively charged sequence
additionally impaired the affinity in this setting (Figure 4D).
Moreover, the complete deletion of the glycerol-core with
its two fatty acids, leaving the peptide with only one fatty
acid (PamCSK4), was not enough to completely block the
inhibitory potential (Figure 4E). In contrast, the glycerol-core
(DAG) without a residual peptide showed no inhibitory binding
to rBPI (Figure 4F). In contrast to the negatively charged
LPS, (R)-Pam3CSK4 is highly positively charged due to the
lysine-rich residual peptide. Interestingly, when looking at the
surface charge distribution pattern of BPI (Figure 4G), both
positively and negatively charged areas can be found around
its N-terminal lipid-binding pocket (24). Consequently, binding
sites are provided for the hydrophilic portion of contrarily
charged ligands. Thus, our results demonstrate that both, the
number of acyl-chains as well as the residual peptide and its
amino-acid composition, influence the binding affinity of bLPs
to BPI.
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FIGURE 2 | Competition of bLPs with lipopolysaccharide for binding to BPI. BPI binding assays with LPS biotin (A–C,F–H) or Pam2CSK4 biotin-coated plates (D,E).
“unc.” shows binding of rBPI in uncoated wells treated otherwise identically (A,B). rBPI was pre-incubated with increasing concentrations of LPS EC (A,D), the
racemate Pam3CSK4 (B), (R)-Pam3CSK4 (C,E) and (S)-Pam3CSK4 (C) or peptidoglycan of S. aureus (PGN SA; F). Furthermore, pre-incubations of rBPI with
different heat-inactivated bacterial lysates are shown (G). Preparations of rBPI and neutrophil BPI of two different sources [BPIN(W) and BPIN(A)] were pre-incubated
with (R)-Pam3CSK4 (H). Absorbance measured at 450 nm for wells with BPI alone was set to 100% to ensure comparability between the different ligands. All results
are shown as means ± SD of three biological replicates.
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FIGURE 3 | Determination of the affinity of BPI to bLPs. MST binding assay
(A–D). Changes in movement in MST were monitored using BPIN(A) NT647
incubated with increasing concentrations of the ligands [LPS EC (A),
(Continued)
FIGURE 3 | Pam3CSK4 (C)] or Pam3CSK4 Fluorescein incubated with
increasing concentrations of BPIN(A) (D). The binding affinity and r
2 values are
indicated. The same assay using NT647-labeled rBPI was used to calculate
KD values for the interactions of the protein to LPS EC, LPS EC BL21, and
(R)-Pam3CSK4 (B). NanoDSF was performed for rBPI incubated with the
indicated ligands (E,F). Temperature-dependent change in fluorescence is
indicated for the wavelength of 350 nm [E, upper part: absolute values, lower
part: first derivate (f’)]. Vertical lines indicate Tm. The shift in melting
temperature (Tshift) caused by the ligands is shown (F). Temperature shifts
above 1◦C are interpreted as the influence of an interaction on the thermal
stability of the protein. Data represent the mean of two (A,C,D) or three (B)
technical replicates or means ± SD of two biological replicates (E,F).
Binding of BPI to Gram-Positive Bacteria
Does Not Depend Solely on bLPs but Also
on LTA
The bLPs are synthesized in several steps as reviewed by
Nakayama et al. (49). The first enzyme Lgt transfers a
diacylglyceryl to the sulfhydryl group of the cysteine of a
pre-prolipoprotein, generating a thioether linkage. Although
deficiency in Lgt does not result in a lack of the specific
lipoproteins (36), the lipoproteins lack the diacyl-anchor, which
is one of the structural motifs that facilitates the binding
of BPI to bLPs as shown in Figure 4. The second enzyme
Lsp subsequently cleaves the signal peptide at the N-terminus
of the diacylglyceryl cysteine of the prolipoprotein. Similarly,
deficiency in Lsp does not result in the absence of the specific
lipoproteins but in their specific modification (36). Since the
signal peptide is not cleaved, the secondary structure of the
lipoproteins is changed and the further coupling of a third
acyl-chain to the central cysteine is prohibited. This acyl-
chain is also important for the binding of BPI to bLPs
(Figure 4).
To test the hypothesis that bLPs are the ligands of BPI
in Gram-positive bacteria, mutants of S. pneumoniae D391cps
lacking the lgt- and/or lsp-gene (36) were tested with the
BPI binding assay (Figure 5A). When whole cell lysates of S.
pneumoniae D391cps, 1cps1lgt, 1cps1lsp, or 1cps1lgt1lsp
were tested, each inhibited binding of rBPI to LPS biotin-coated
wells. However, inhibition was less pronounced for the Lgt-, Lsp-,
or double-deficient strains in the intermediate concentration (p
= 0.004, n= 4, unpaired Student’s t-test).
Concerning additional binding partners of BPI, we examined
LTA, which is anchored to the bacterial cell membrane via a
lipophilic anchor. As exemplified in Figure S3, the common
motif for all LTAs is a DAG, which is further substituted
with a glycosyl moiety at the O-3 position. These glycosyl
moieties, as well as the structures of present repeating units
[polyglycerolphosphate (type I), complex glycosyl-glycerol-
phosphate (type II + III), glycosyl-ribitol-phosphate (type IV)
or glycosyl-phosphate (type V) containing polymers] are highly
variable between different species of Gram-positive bacteria
(50). As representative samples, we tested LTA preparations
of two organisms with completely different LTA structures, S.
pneumoniae [type IV LTA; (14)] and S. aureus [type I LTA; (39)],
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FIGURE 4 | Structural requirements for binding of bLPs to BPI. BPI binding assay (A–F). Lipopeptides with modified structure as well as DAG were tested for their
potential to inhibit binding of rBPI to LPS biotin-coated wells (A–F). Absorbance measured at 450 nm for wells with rBPI alone was set to 100% to ensure
comparability between the different ligands. All results are shown as means ± SD of at least four biological replicates. R1 = CH3(CH2)14. Electrostatic charge surface
of the BPI structure (G). N-terminal lipid-binding pocket surrounded by differently charged areas is depicted with phosphatidylcholine as ligand.
for their BPI binding potential. In order to ensure the purity
of LTAs, not only LTA SP and LTA SA, but also LTA of the
corresponding Lgt-deficient mutants (LTA SP1lgt, LTA SA1lgt)
were tested. All competed for the binding of rBPI to LPS biotin
as determined by the BPI binding assay (Figures 5B,C,G,H).
This inhibition was less pronounced in experiments performed
with LTA purified from Lgt-deficient strains, showing that,
analogously to the synthetic bLPs, naturally occurring bLP
variants are indeed binding partners of BPI in S. pneumoniae
D391cps as well as S. aureus 113. The binding potential
to rBPI tended to be higher for LTA SA1lgt than LTA
SP1lgt (Figures 5C,H). In accordance with this observation,
MST also showed slightly superior binding of LTA SA1lgt
compared to LTA SP1lgt (Figures 5F,I). Thus, LTAs from
different bacterial genera exhibit differences in their affinity to
BPI.
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FIGURE 5 | LTA is an additional ligand of BPI in Gram-positive bacteria. BPI binding assay (A–E, G,H). MST binding assay (F,I). Lysates of S. pneumoniae D391cps,
D391cps1lgt (SP1lgt), D391cps1lsp (SP1lsp) and D391cps1lgt1lsp (SP1lgt1lsp; 50µg/ml) were incubated with rBPI to evaluate their potential to inhibit the
binding to LPS biotin-coated wells (A, NT: not treated). Statistics for comparison were performed with the unpaired Student’s t-test (p-value *p = 0.004). LTA SP and
LTA SA were tested for their potential to inhibit the binding of rBPI to LPS biotin-coated wells (B,G). To correct for the effects of contaminating bLPs, LTAs of the
corresponding 1lgt strains were tested (C,H). Data for LTA SP1lgt-N2H4 as well as WTA SP1lgt are shown (D,E). Absorbance measured at 450 nm for wells with
rBPI alone was set to 100% to ensure comparability between the different ligands. Results are shown as means ± SD of three (B–E, G,H) or four (A) biological
replicates. rBPI NT647 was monitored in MST when incubated with increasing concentrations of LTA SP1lgt and WTA SP1lgt (F) as well as increasing concentrations
of LTA SA1lgt (I). KD and r
2 values are indicated for LTA SP1lgt and LTA SA1lgt (F,I). Data represent the mean of three technical replicates (F,I).
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FIGURE 6 | Influence of BPI on TNFα secretion of PBMCs in response to bLPs and lysates of S. pneumoniae D391cps. TNFα-ELISA of the supernatants of PBMCs
stimulated with TLR-ligands [LPS EC, (R)-Pam3CSK4 or (R)-FSL-1] ± rBPI at the indicated concentrations for 18 h (A). Independent titration experiments performed in
four different donors are indicated as relative increase compared to cytokine secretion with TLR ligand alone (A). The relative increase in TNFα, IL-6, and IL-8 in the
supernatants of PBMCs stimulated with (R)-Pam3CSK4 ± rBPI is represented (C). One donor (•) is not shown in (C) for stimulation since IL-6 was beyond the linear
range of the ELISA. The relative increase in TNFα in the supernatants of PBMCs stimulated with (R)-Pam3CSK4 ± BPIN(A) or LTA SP ± rBPI is summarized (B,D).
PBMCs were stimulated with lysates of S. pneumoniae D391cps and S. aureus 113 and the relative change in secreted TNFα, IL-6, and IL-8 caused by the addition
of BPI is shown (E,F). Results of independent stimulations of PBMCs of four (A,D) or seven (B,C,E,F) different donors are shown. Each symbol represents an
individual donor (B–F). Unless otherwise indicated, the BPI concentration used was 500 nM. Statistics for comparison of the relative cytokine secretion ± BPI were
performed with the paired Student’s t-test (p-values are indicated, B–F). Results are shown as means ± SEM (A).
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Next the structural motif necessary for binding of BPI to LTA
was determined. As we have shown for bLPs, the binding to BPI
was dependent on the acyl-chains. To evaluate the role of the
diacyl-anchor of LTA, LTA SP1lgt was treated with anhydrous
hydrazine for removal of the acyl moieties from the anchor (LTA
SP1lgt-N2H4, depicted in Figure S3B). As shown in Figure 5D,
competition in binding to rBPI of LTA SP1lgt-N2H4 was
markedly reduced compared to LTA SP1lgt. As an independent
approach, WTA of S. pneumoniae was used. S. pneumoniaeWTA
shares an identical chemical structure within its repeating units to
LTA, but due to covalent attachment to the peptidoglycan (PGN),
it lacks the diacyl-anchor that anchors LTA to the cytoplasmic
membrane (14, 51). To mimic the natural situation as closely
as possible, but still removing all other potential bioactive
cell wall components, we used the pneumococcal PGN-WTA
complex after treatment with the pneumococcal amidase LytA
for our investigations. In this complex, pneumococcal WTAs
are intact and bound to polymeric PGN-derived [MurNAc-
GlcNAc]x-chains that are devoid of peptides (38). As shown
in Figure 5E, this WTA SP1lgt did not compete with LPS
biotin for binding to rBPI. It should be noted that the MW
of PGN-WTA cannot be determined exactly. Thus, as stated in
the methods, concentrations exceeding that of LTA were tested.
Correspondingly, WTA SP1lgt also showed no binding to rBPI
NT647 in MST (Figure 5F).
In summary, we describe two components originating from
Gram-positive bacteria as new ligands of BPI including not only
synthetic, but also naturally occurring bLPs and LTA. Interaction
of LTA with BPI depends on its diacyl-anchor.
BPI Enhances the Response to bLPs in
PBMCs
Next we investigated whether BPI is able to neutralize or
indeed enhances the stimulatory potential of the newly described
ligands. First, we optimized the PBMC cell culture conditions
in order to achieve optimal neutralization of LPS by rBPI
(Figure 6A). When bLPs were added to the PBMCs together
with rBPI, no neutralization effect could be observed. In contrast,
when the rBPI concentration was increased, TNFα secretion was
gradually enhanced for both tri-acylated [(R)-Pam3CSK4] and di-
acylated [(R)-FSL-1] bLPs (Figure 6A). This enhancement was
not only detected for TNFα, but also for IL-6 and IL-8 with
PMBCs of seven different donors (Figure 6C, Figures S4A,B).
BPI derived from neutrophils had an even more pronounced
function compared with the recombinant protein (Figure 6B,
Figure S4C). As tested for (R)-Pam3CSK4, the enhancing effect
was more efficient when lower concentrations of the stimulant
were used as seen for both BPI preparations (10 nM vs. 1 nM).
Since bLPs were shown to be bound by rBPI in the lysate
of S. pneumoniae D391cps (Figure 5A), we tested whether
rBPI would influence the stimulatory potential of this lysate.
Strikingly, PBMCs responded with a remarkable increase in
TNFα, IL-6, and IL-8 secretion in the presence of rBPI in
seven different donors (Figure 6E, Figure S5A). As expected, the
corresponding lysate of the 1lgt1lsp-mutant ± rBPI stimulated
only weakly (Figure S5A). When lysates of S. aureus 113 were
tested on PBMCs, TNFα, IL-6, and IL-8 secretion was also
increased by addition of rBPI (Figure 6F, Figure S5C). Three
independent lysates of S. pneumoniae D391cps, S. pneumoniae
D391cps1lgt1lsp and S. aureus 113 were tested with comparable
results (Figures S5B,D). As we have published previously (14),
LTA SA1lgt did not show stimulation of TNFα secretion,
and LTA SP1lgt stimulated TNFα secretion only at high
concentrations (Figure S6). BPI incubated with LTA SP1lgt
at the indicated concentrations increased secretion of TNFα
compared to LTA SP1lgt alone (Figure 6D). LBP depends on
CD14 for the transfer of LPS or bLPs to the corresponding TLRs
(6, 9, 29). However, expression of TLR2 and CD14 in HEK293T
cells is not sufficient to enhance immune stimulation of bLPs by
BPI (Figure S7).
In summary, BPI enhances the immune response toward
Gram-positive ligands in PBMCs when synthetic bLPs, LTA
SP1lgt as well as lysates of Gram-positive bacteria are used.
DISCUSSION
BPI is a constitutively highly expressed protein in human
neutrophils (30, 52), and has been recognized as a bactericidal
protein toward Gram-negative bacteria (20, 30). Concerning the
pathophysiological reason for the elevation of BPI in Gram-
positive meningitis, direct bacterial killing seems unlikely, as
this could not be shown for Gram-positive bacteria in previous
studies (30, 31). However, rBPI21 protects mice against S.
pneumoniae infection after intranasal application, an effect
possibly caused by interactions with bacterial ligands (53). Here,
we defined bLPs and LTA of Gram-positive origin as new ligands
of BPI.
The finding that bLPs and LTAs compete with LPS for
binding to BPI indicates that all three types of ligands apparently
use a common binding site. This site is probably the N-
terminal lipid-binding pocket described by Beamer et al. which
is able to incorporate hydrophobic acyl-chains as shown for
phosphatidylcholine (24). The dependency on the acyl-chains in
BPI binding to bLPs and LTAs is in line with their important
role for the binding of BPI to LPS (54). BPI binds to a variety
of LPS preparations of different bacterial origin, all containing
negatively charged anionic groups (54). Initially, it was surprising
that the positive charge of bLPs favored high affinity binding to
BPI, but this contradiction could be explained by the negatively
and positively charged areas surrounding the N-terminal lipid-
binding pocket of BPI. These opposing areas likely facilitate the
stabilization of the hydrophobic interaction of different ligands.
According to our data, BPI correlates with pro-inflammatory
markers like TNFα in CSF of patients with pneumococcal
meningitis. Importantly, binding of BPI to bLPs and LTA SP
augmented the stimulatory potential in cell culture experiments.
For bLPs, BPI enhanced the potential of TLR2/1-specific bLPs,
as exemplified for (R)-Pam3CSK4, TLR2/6-specific bLPs, as
exemplified for (R)-FSL-1, and natural bLPs, as exemplified by
comparison of lysates of Lgt-deficient with the corresponding
wild-type strain of S. pneumoniae. These effects are surprising
and in contrast to the known neutralization of the TLR4-ligand
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LPS. In principle, the immune-enhancing capacity toward bLPs
seems to be conserved in BPI and LBP. Whereas, LBP depends
on CD14 for its function (6, 9, 29), CD14 is not essential for
binding of BPI to PBMCs (27, 28). In accordance, CD14 was
not sufficient to enable the enhancing effect of BPI in HEK293T
cells transfected with a TLR2 expressing vector. Although the
exact mechanism used by BPI still has to be elucidated, our
data indicate a conservation of the lipid transfer function as
known for other members of the TULIP family such as LBP or
CETP. In this aspect, the conformational change of BPI upon
exposure to LPS EC and bLPs as found in NanoDSF is congruent
with data for CETP, which increases the diameter of its intra-
molecule tunnel when bound to its specific binding partners,
and consequently promotes the transfer of cholesteryl esters
(55). A corresponding transport function might be operative
for bLPs. The KD value of 5.2 nM found in our study for
BPI from neutrophilic source and LPS EC was in line with
the published KD of 4.1 nM for lipid A of E. coli J5 (56).
Of note, the overall affinity of different bLPs to BPI tended
to be lower than that seen for LPS. This difference seems
important for either neutralization in case of high affinity or
enhancement of the cell stimulatory activity when the affinity is
lower. Thus, higher affinity, e.g. caused by additional interaction
with the cationic tip, or other unknown factors, might omit
transfer of LPS. In contrast to LPS, non-immune stimulating
substances like synthetic bLPs lacking dihydroxypropylcystein
such as PamCSK4 or 2-acyl-chains in position C1 and C2 of
the glycerol such as Pam2∗CSK4, might be transferred by BPI
but will not become immune stimulatory as they lack TLR2-
stimulatory potential (57). In conclusion, we postulate that BPI
is promiscuous in binding and transferring bacterial derived
ligands like glycolipids or lipopeptides, but specificity with regard
to the induced pro-inflammatory response is determined by the
respective recognizing receptor.
Surprisingly and in contrast to BPI, we found no correlation
between LBP and cytokines in the CSF samples. Although
BPI and LBP were described as antagonists with respect to
their action toward LPS (21), LBP can not only increase (11),
but also antagonizes the stimulatory potential of LPS when
LBP concentrations are high (58, 59). This could be true for
bLPs as well. Thus, the function of both proteins seems to
be complementary and not merely antagonistic. Since BPI is
secreted locally from neutrophils and epithelial cells (23, 60, 61),
and LBP is instead released mainly systemically from hepatocytes
(62, 63), their function is possibly adjusted to different sites of
action.
As shown previously, BPI lacks a major neutralizing effect
on endotoxin within meningococcal bacterial outer membrane
vesicles in monocyte-derived dendritic cells (64). In line with
our data, this might also be a result of the immune-enhancing
potential of BPI toward bLPs, therefore masking the neutralizing
capacity toward the endotoxin. In human neutrophils, the
combination of BPI and E. coli, but not of BPI and LPS
alone, was found to enhance degranulation in neutrophils (26),
which likewise could be caused by the interaction between BPI
and bLPs present in E. coli. Recently, a significant enhanced
regeneration of bone marrow cells by repeated application of
high doses of rBPI21 to mice after total body irradiation was
described (65). Simultaneously, an increase of pro-inflammatory
cytokines, such as TNFα and IL-6, was found in plasma.
The underlying mechanism for this finding remained unclear,
albeit effects of rBPI21 on endothelium and pericytes in the
hematopoietic microenvironment were suggested. The pro-
inflammatory potential of BPI toward TLR2-ligands is a process
possibly involved. Irradiation causes damage to the epithelial
barrier of the gut and consequentially transition of the intestinal
microbiota (66), which is able to promote myeloid differentiation
to granulocyte and/or monocyte progenitors in the bone-
marrow (67). Treatment of irradiated mice with a TLR2 agonist
also results in accelerated hematopoiesis (68). BPI most likely
enhances the TLR-mediated immune response caused by released
bacteria after total body irradiation of mice. In a translational
perspective, co-application of TLR2 ligands with BPI might
even enhance effects of BPI on haematopoesis and therefore
facilitate dose reduction and future cost effective application to
patients.
Compared to other antimicrobial peptides, BPI is unique
since it neutralizes LPS with high efficiency on the one hand,
and specifically enhances the inflammatory response to bLPs
and LTA on the other. Based on these findings, BPI is a soluble
pattern recognition molecule with opposing effects on different
bacterial ligands, and therefore has the potential to adapt the
immune response according to the class of bacteria encountered.
Further investigations concerning the pro-inflammatory
functions of BPI are needed as they will contribute to the
principle understanding of innate immunity against bacterial
infections.
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